Table 3 Prevalence and adjusted ORs for thrombophilia among women with VTE
| Â | Â | Â | Â | Â | Excluding women |
|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | with malignancy, |
| Â | Â | Â | Â | Â | recent surgery or |
| Â | All women | immobilization* | |||
| Â | Number (%) | Number (%) | Â | Â | Â |
| Â | of cases with | controls with | Â | Â | Â |
|  | thrombophilia | thrombophilia | Crude OR | Adjusted OR†| Adjusted OR‡ |
Thrombophilia factor | factor | factor | (95% CI) | (95% CI) | (95% CI) |
Prothrombin (++ or +/-) | 12 (9.3) | 3 (2.3) | 4.3 (1.2-15.6) | 4.3 (1.1-17.4) | 7.8 (1.0-64.2) |
Factor V (+/+ or +/-) | 21 (16.3) | 5 (3.9) | 4.8 (1.8-13.2) | 3.9 (1.4-10.8) | 3.6 (1.2-11.4) |
MTHFR C677T (+/+) | 19 (14.7) | 13 (10.1) | 1.5 (0.7-3.3) | 1.4 (0.6-3.1) | 1.1 (0.4-2.9) |
MTHFR 1298C (+/+) | 68 (52.7) | 69 (53.5) | 1.0 (0.6-1.6) | 1.0 (0.6-1.7) | 1.2 (0.6-2.3) |
MTRR A66G (+/+) | 42 (32.6) | 35 (27.1) | 1.3 (0.8-2.2) | 1.1 (0.6-2.2) | 0.9 (0.4-2.2) |
Any MTHFR (+/+) or A66G MTRR (+/+) | 90 (69.8) | 88 (68.2) | 1.1 (0.6-1.8) | 1.0 (0.6-2.0) | 1.1 (0.5-2.3) |
Fasting plasma hyperhomocysteinemia$ | 46 (35.6) | 5 (4.0) | 13.7 (5.2-36.0) | 17.8 (4.2-74.9) | 11.6 (2.7-50.5) |